ASTELLAS PHARMA INC. 
By
February 5, 2014
TOKYO, February 5, 2014 - Astellas Pharma Inc. ("Astellas"; President and CEO: Yoshihiko Hatanaka) announced today that it will implement the following revisions to its global management structure effective from April 1, 2014:
【Global Management Structure】
1. Global Development Head will report to Chief Medical Officer ("CMO") from April 1, 2014 (currently reports to CEO).
2. Global Regulatory Affairs Head, Global Clinical and Research Quality Assurance Head, and Global Quality Assurance Head will report to CMO from April 1, 2014 (currently report to QA and RA Head of Astellas Pharma Inc.). Accordingly, the position of QA and RA Head of Astellas Pharma Inc. will be dissolved.
Objective
For the purpose of enhancing global product compliance and the overall synergy with Global Development, Astellas has decided that all Heads of Global Development, GRA*, GCRQA*, and GQA* will report to CMO, while Heads of GPV* and GMA* have already reported to CMO since April 1, 2013.
* GPV: Global Pharmacovigilance GMA: Global Medical Affairs GRA: Global Regulatory Affairs
GCRQA: Global Clinical and Research Quality Assurance
GQA: Global Quality Assurance
【Top Management Structure】
Along with revisions to the global management structure, new global report line structure will be changed as below, effective from April 1, 2014.
Title | Divisional Responsibilities |
President and CEO (Chief Executive Officer) | Internal Auditing, Medical Affairs, Drug Discovery Research, Technology, Japan Sales & Marketing, Asia/Oceania Business, EMEA Operations, Americas Operations |
Executive Vice President, CAO & CCO (Chief Administrative Officer & Chief Compliance Officer) | External Relations, General Affairs, Human Resources, Legal & Compliance, Executive Office |
Senior Vice President and CFO (Chief Financial Officer) | Corporate Finance & Control, Accounting & Tax, Corporate Communications, Procurement, Information Systems |
Senior Vice President and CSTO (Chief Strategy Officer) | Corporate Planning, Product and Portfolio Strategy, Licensing & Alliances, Innovation Management, Intellectual Property |
CMO (Chief Medical Officer) | Global Development, GPV, GMA, GRA, GCRQA, GQA |
2
Global Management Committee
The members of the Global Management Committee will be changed as below, effective from
April 1, 2014.
Global Management Committee | |
Issues for deliberation: Globally important issues spanning function and geographical regions | |
President and CEO | Yoshihiko Hatanaka |
Executive Vice President, CAO & CCO | Yoshirou Miyokawa |
Senior Vice President and CFO | Yasumasa Masuda |
Senior Vice President and CSTO | Kenji Yasukawa |
CMO and President, Global Development | Sef Kurstjens |
Senior Vice President and President, Drug Discovery Research | Wataru Uchida |
Senior Vice President and President, Technology | Mitsunori Matsuda |
Senior Vice President and President, Sales & Marketing Japan | Yukihiko Sato |
Senior Vice President and President, Asia/Oceania Business | Masatoshi Kuroda |
President and CEO EMEA Operations | Ken Jones |
President and CEO Americas Operations | Masao Yoshida |
###
For inquiries or additional information
Astellas Pharma Inc. Corporate Communications
TEL: +81-3-3244-3201, FAX:+81-3-5201-7473
http://www.astellas.com/en
3
|
distributed by
|
